Adma Biologics selloff brings attractive entry point, says Mizuho

Mizuho says Adma Biologics shares corrected 16% on the disclosure of its long-standing auditor CohnReznick will conclude its services at the end of the current filing period. Importantly, CohnReznick is standing behind its previous accounting opinions on all reportable periods dating back several years, the analyst tells investors in a research note. Mizuho says that with a new auditor expected to be announced imminently and current Asceniv trends appearing stable, it recommends investors take advantage :of what is now an attractive entry point.”